ClinicalTrials.gg
Not yet recruitingNCT06673784Updated Nov 5, 2024

Evaluation and Risk Factors of Post-traumatic Endophthalmitis

An observational study in Endophthalmitis, sponsored by Assiut University. Not yet recruiting. Per ClinicalTrials.gov, last updated 2024-11-05.

Sponsored by Assiut University · Observational

From the registry’s dates

  • Primary completion was expected by Feb 2026, 8 months ago, but the record still lists the study as not yet recruiting.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
41
Sex
All
01

Study summary

  1. identify the incidence of post-traumatic endophthalmitis and the related risk factors influencing its development.
  2. study the clinical- microbiological profile and evaluate the functional and anatomical outcomes of post-traumatic endophthalmitis (PPTE).
02

Conditions studied

  • Endophthalmitis

Browse trials for

03

In context

Endophthalmitis

65 studies on the registry are indexed under Endophthalmitis; 9 are open to participants now.

This study's planned enrollment of 41 is below the median of 100 across 20 observational studies indexed under Endophthalmitis.

Browse Endophthalmitis studies →

Lead sponsor

Assiut University is the lead sponsor of 5,078 studies on the registry; 2,178 are open to participants now.

Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Evaluation and risk factors of post-traumatic endophthalmitis with general and optical examination on patients exposed to eye trauma and developed post-traumatic endophthalmitis

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients exposed to eye trauma and developed post-traumatic endophthalmitis

Exclusion criteria

Exclusion Criteria:

  • Patients who refuse to sign in this study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
41 participants (estimated)
Patient registry
No

Groups and cohorts

  • Evaluation of post-traumatic endophthalmitis

    1. conception 2. acquisition of data 3. analysis of data

    Diagnostic Test: ophthalmic saline eye drops · Drug: Saline

Interventions

  • Diagnostic testophthalmic saline eye drops

    for optical examination

  • DrugSaline

    Most one natural and not effects on study

06

What researchers measure

Primary outcomes

  1. Knowledge of clinical features outcomes of post-traumatic endophthalmitis

    Knowledge of clinical features which will be shown due to post-traumatic endophthalmitis

    Time frame: Baseline

Secondary outcomes

  1. The factors associated with a worse prognosis in post-traumatic endophthalmitis

    Discrimination the worst prognosis in post-traumatic endophthalmitis

    Time frame: Baseline

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Alfaro DV, Roth DB, Laughlin RM, Goyal M, Liggett PE. Paediatric post-traumatic endophthalmitis. Br J Ophthalmol. 1995 Oct;79(10):888-91. doi: 10.1136/bjo.79.10.888. PubMed 7488575 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 5, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06673784
Lead sponsor
Assiut University
Responsible party
Hadeer Gamal AbdElmohsen Ahmed (Doctor, Assiut University) — Principal investigator
First posted
Nov 5, 2024
Start date
Nov 10, 2024 (estimated)
Primary completion
Feb 28, 2026 (estimated)
Completion
Mar 2026 (estimated)
Last update
Nov 5, 2024

Study contacts

Hadeer Gamal AbdElmohsen, 3
Contact
hadeergamal294@gmail.com
00201091593658 ext. 01147084398
Mohamed Sayed Saad, 1
Contact
mohsayedsaad@aun.edu.eg
00201001825024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion